About 1 in 150 babies are born with a chromosomal abnormality. Every pregnant woman is at risk of giving birth to a baby with a chromosomal disorder and should undergo prenatal testing to reduce the risk.

The Non-Invasive Fetal Trisomy Test (NIFTY/NIPT/NIPS) utilizes Next-Generation Sequencing (NGS) technology. By analyzing cell-free fetal DNA extracted from a maternal peripheral blood sample, it can safely screen for fetal chromosomal abnormalities from 10 weeks of gestation onwards.

This test can detect common trisomy syndromes, including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), as well as offering screening options for sex chromosome aneuploidies and other chromosomal aneuploidies, chromosomal deletions/duplications, and fetal sex determination.